Francisco J Diaz-Corrales

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5149050/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa. Journal of Clinical Medicine, 2022, 11, 2170.	1.0	8
2	Dissecting the role of EYS in retinal degeneration: clinical and molecular aspects and its implications for future therapy. Orphanet Journal of Rare Diseases, 2021, 16, 222.	1.2	16
3	Analysis of gene network bifurcation during optic cup morphogenesis in zebrafish. Nature Communications, 2021, 12, 3866.	5.8	14
4	Biocompatibility Study of a Commercial Printed Circuit Board for Biomedical Applications: Lab-on-PCB for Organotypic Retina Cultures. Micromachines, 2021, 12, 1469.	1.4	3
5	Retinal pigment epithelium degeneration caused by aggregation of PRPF31 and the role of HSP70 family of proteins. Molecular Medicine, 2020, 26, 1.	1.9	45
6	Generation of a human iPS cell line (CABi003-A) from a patient with age-related macular degeneration carrying the CFH Y402H polymorphism. Stem Cell Research, 2019, 38, 101473.	0.3	1
7	Electrostimulation in an autonomous culture lab-on-chip provides neuroprotection of a retinal explant from a retinitis pigmentosa mouse-model. Sensors and Actuators B: Chemical, 2019, 288, 337-346.	4.0	11
8	Subretinal Transplant of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium on Nanostructured Fibrin-Agarose. Tissue Engineering - Part A, 2019, 25, 799-808.	1.6	15
9	Generation and characterization of the human iPSC line CABi001-A from a patient with retinitis pigmentosa caused by a novel mutation in PRPF31 gene. Stem Cell Research, 2019, 36, 101426.	0.3	1
10	Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 393-406.	2.5	88
11	Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 381-390.	2.5	89
12	The Resveratrol Prodrug JC19 Delays Retinal Degeneration in rd10 Mice. Advances in Experimental Medicine and Biology, 2019, 1185, 457-462.	0.8	10
13	Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bclâ€2 expression. CNS Neuroscience and Therapeutics, 2018, 24, 448-455.	1.9	17
14	Generation of a human iPS cell line from a patient with retinitis pigmentosa due to EYS mutation. Stem Cell Research, 2018, 33, 251-254.	0.3	4
15	Prevalence of Age-Related Macular Degeneration in Europe. Ophthalmology, 2017, 124, 1753-1763.	2.5	337
16	Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: An approach of gene therapy to treat retinitis pigmentosa. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2251-2260.	1.7	18
17	pEPito-driven <i>PEDF</i> Expression Ameliorates Diabetic Retinopathy Hallmarks. Human Gene Therapy Methods, 2016, 27, 79-86.	2.1	22
18	Striatal Astrocytes Act as a Reservoir for L-DOPA. PLoS ONE, 2014, 9, e106362.	1.1	48

#	Article	IF	CITATIONS
19	Hypoxia Increases the Yield of Photoreceptors Differentiating from Mouse Embryonic Stem Cells and Improves the Modeling of Retinogenesis In Vitro. Stem Cells, 2013, 31, 966-978.	1.4	36
20	Study of Cerebello-Thalamocortical Pathway by Transcranial Magnetic Stimulation in Parkinson's Disease. Brain Stimulation, 2013, 6, 582-589.	0.7	75
21	Astrogliosis promotes functional recovery of completely transected spinal cord following transplantations of hESC-derived oligoden-drocyte and motoneuron progenitors. Cytotherapy, 2013, 15, S47.	0.3	Ο
22	ATR localizes to the photoreceptor connecting cilium and deficiency leads to severe photoreceptor degeneration in mice. Human Molecular Genetics, 2013, 22, 1507-1515.	1.4	27
23	Transplantation of Melanocytes Obtained from the Skin Ameliorates Apomorphine-Induced Abnormal Behavior in Rodent Hemi-Parkinsonian Models. PLoS ONE, 2013, 8, e65983.	1.1	7
24	Centrosomal aggregates and Golgi fragmentation disrupt vesicular trafficking of DAT. Neurobiology of Aging, 2012, 33, 2462-2477.	1.5	11
25	Sensory perception changes induced by transcranial magnetic stimulation over the primary somatosensory cortex in Parkinson's disease. Movement Disorders, 2011, 26, 2058-2064.	2.2	9
26	Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 556-564.	3.3	59
27	Neuroprotective effects of zonisamide target astrocyte. Annals of Neurology, 2010, 67, 239-249.	2.8	109
28	Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. Acta Neurologica Scandinavica, 2010, 122, 41-45.	1.0	37
29	Prevalence and clinical features ofLRRK2mutations in patients with Parkinson's disease in southern Spain. European Journal of Neurology, 2009, 16, 957-960.	1.7	32
30	Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells. Neurotoxicity Research, 2008, 14, 295-305.	1.3	7
31	Glucose-6-phosphate dehydrogenase activity in Parkinson's disease. Journal of Neurology, 2008, 255, 1850-1851.	1.8	8
32	Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neuroscience Research, 2008, 60, 106-113.	1.0	42
33	Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats. Neuroscience Research, 2008, 60, 355-363.	1.0	8
34	Suppression of p53-activated gene, PAG608, attenuates methamphetamine-induced neurotoxicity. Neuroscience Letters, 2007, 414, 263-267.	1.0	16
35	Centrosome overduplication induced by rotenone treatment affects the cellular distribution of p53 tumor suppressor protein in the neuroblastoma B65 cell line. Psychiatry and Clinical Neurosciences, 2006, 60, S18.	1.0	3
36	Embryonic expression of pericentrin suggests universal roles in ciliogenesis. Development Genes and Evolution, 2006, 216, 537-542.	0.4	29

#	Article	IF	CITATIONS
37	Methamphetamineâ€induced dopaminergic neurotoxicity is regulated by quinone formationâ€related molecules. FASEB Journal, 2006, 20, 571-573.	0.2	101
38	Dopamine Agonist Pergolide Prevents Levodopa-Induced Quinoprotein Formation in Parkinsonian Striatum and Shows Quenching Effects on Dopamine-Semiquinone Generated in Vitro. Clinical Neuropharmacology, 2005, 28, 155-160.	0.2	17
39	L-DOPA treatment from the viewpoint of neuroprotection. Journal of Neurology, 2005, 252, iv23-iv31.	1.8	26
40	Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generatedin vitro. Neurological Research, 2005, 27, 533-539.	0.6	9
41	Rotenone induces aggregation of γ-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration. Neuroscience, 2005, 133, 117-135.	1.1	55
42	Nocardia otitidiscaviarum (GAM-5) induces parkinsonian-like alterations in mouse. Brazilian Journal of Medical and Biological Research, 2004, 37, 539-548.	0.7	16
43	Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Research, 2004, 1029, 120-123.	1.1	117
44	DISC1 localizes to the centrosome by binding to kendrin. Biochemical and Biophysical Research Communications, 2004, 317, 1195-1199.	1.0	100
45	Rotenone induces disassembly of the Golgi apparatus in the rat dopaminergic neuroblastoma B65 cell line. Neuroscience Letters, 2004, 354, 59-63.	1.0	17
46	Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Medica Okayama, 2004, 58, 221-33.	0.1	32